Danielle Brill
Stock Analyst at Truist Financial
(4.62)
# 909
Out of 5,004 analysts
412
Total ratings
51.2%
Success rate
12.4%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Reiterated: Hold | n/a | $33.30 | - | 16 | Sep 24, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | n/a | $33.91 | - | 5 | Sep 23, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | n/a | $526.19 | - | 11 | Sep 23, 2026 | |
| MAZE Maze Therapeutics | Reiterated: Buy | $64 | $26.05 | +145.68% | 6 | Sep 22, 2026 | |
| IRON Disc Medicine | Reiterated: Buy | n/a | $65.24 | - | 22 | Sep 21, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | n/a | $255.96 | - | 19 | Sep 18, 2026 | |
| CLYM Climb Bio | Reiterated: Buy | n/a | $11.66 | - | 8 | Sep 4, 2026 | |
| SLDB Solid Biosciences | Initiated Coverage: Buy | $20 | $7.29 | +174.35% | 1 | Aug 21, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,030 → $1,095 | $959.49 | +14.12% | 34 | Aug 18, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $102 → $107 | $65.57 | +63.18% | 15 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 → $25 | $5.36 | +366.42% | 7 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $195 | $117.83 | +65.49% | 10 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $23.67 | +153.49% | 12 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $616 | $280.78 | +119.39% | 3 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $128 | $88.55 | +44.55% | 9 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $29 → $34 | $41.26 | -17.60% | 20 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $207 | $138.16 | +49.83% | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $213 | $138.40 | +53.90% | 24 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $235 | $227.60 | +3.25% | 19 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.78 | +296.83% | 3 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $8.99 | $38.23 | n/a | 23 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $7.40 | n/a | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $20.68 | n/a | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $32.58 | n/a | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $79 | $60.26 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $20.39 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $62.67 | n/a | 21 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $150 | $18.67 | n/a | 36 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 → $50 | $36.94 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.94 | n/a | 19 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $10 | $4.80 | n/a | 5 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $11.37 | n/a | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $45 | $11.62 | n/a | 2 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $40.85 | n/a | 10 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $195.09 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $5 | $13.99 | n/a | 5 | Nov 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $150.93 | n/a | 1 | Jul 26, 2016 |
Immunovant
Sep 24, 2026
Reiterated: Hold
Price Target: n/a
Current: $33.30
Upside: -
Rapport Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $33.91
Upside: -
Vertex Pharmaceuticals
Sep 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $526.19
Upside: -
Maze Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: $64
Current: $26.05
Upside: +145.68%
Disc Medicine
Sep 21, 2026
Reiterated: Buy
Price Target: n/a
Current: $65.24
Upside: -
Alnylam Pharmaceuticals
Sep 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $255.96
Upside: -
Climb Bio
Sep 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.66
Upside: -
Solid Biosciences
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.29
Upside: +174.35%
argenx SE
Aug 18, 2026
Reiterated: Buy
Price Target: $1,030 → $1,095
Current: $959.49
Upside: +14.12%
BridgeBio Pharma
Aug 12, 2026
Reiterated: Buy
Price Target: $102 → $107
Current: $65.57
Upside: +63.18%
Aug 12, 2026
Reiterated: Buy
Price Target: $43 → $25
Current: $5.36
Upside: +366.42%
Aug 10, 2026
Reiterated: Buy
Price Target: $195
Current: $117.83
Upside: +65.49%
Aug 10, 2026
Reiterated: Buy
Price Target: $60
Current: $23.67
Upside: +153.49%
Aug 7, 2026
Reiterated: Buy
Price Target: $616
Current: $280.78
Upside: +119.39%
Aug 6, 2026
Reiterated: Buy
Price Target: $128
Current: $88.55
Upside: +44.55%
Aug 5, 2026
Reiterated: Hold
Price Target: $29 → $34
Current: $41.26
Upside: -17.60%
Aug 5, 2026
Reiterated: Buy
Price Target: $207
Current: $138.16
Upside: +49.83%
Aug 3, 2026
Reiterated: Buy
Price Target: $200 → $213
Current: $138.40
Upside: +53.90%
Jul 31, 2026
Reiterated: Buy
Price Target: $235
Current: $227.60
Upside: +3.25%
Jul 31, 2026
Reiterated: Buy
Price Target: $15
Current: $3.78
Upside: +296.83%
Dec 10, 2024
Reiterated: Buy
Price Target: $20 → $8.99
Current: $38.23
Upside: n/a
Nov 18, 2024
Reiterated: Buy
Price Target: $18
Current: $7.40
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $20.68
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $32.58
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $79
Current: $60.26
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $20.39
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $62.67
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $150
Current: $18.67
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $52 → $50
Current: $36.94
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $6.94
Upside: n/a
May 16, 2022
Reiterated: Buy
Price Target: $24 → $10
Current: $4.80
Upside: n/a
Jun 30, 2021
Initiated Coverage: Hold
Price Target: n/a
Current: $11.37
Upside: n/a
May 27, 2020
Reiterated: Buy
Price Target: $35 → $45
Current: $11.62
Upside: n/a
Feb 13, 2020
Reiterated: Hold
Price Target: n/a
Current: $40.85
Upside: n/a
Dec 16, 2019
Reiterated: Buy
Price Target: $125
Current: $195.09
Upside: n/a
Nov 7, 2019
Reiterated: Hold
Price Target: $6 → $5
Current: $13.99
Upside: n/a
Jul 26, 2016
Downgraded: Hold
Price Target: n/a
Current: $150.93
Upside: n/a